Materials and methods
Unless otherwise noted, all reagents were purchased from commercial suppliers and used without further purification. DCM (dichloromethane) was dried using PURESOLV-columns (Innovative Technology Inc.). Dry N,N-dimethylformamide was purchased from ACROS and stored under argon. 3-(4-(Prop-2-yn-1-yloxy)phenyl)-1,2,4,5-tetrazine (1), 1 2-((tert-butoxycarbonyl)amino)-3-(4-(prop-2-yn- 4 were prepared following known procedures. All other solvents were distilled prior to use. Drying of organic solvents after extraction was performed using anhydrous Na2SO4 or MgSO4 and subsequent filtration. Reactions were carried out under an atmosphere of argon in air-dried glassware with magnetic stirring. Sensitive liquids were transferred via syringe. Thin layer chromatography was performed using TLC alumina plates (Merck, silica gel 60, fluorescence indicator F254, or Merck, aluminum oxide neutral, fluorescence indicator F254). Preparative column chromatography was performed using a Büchi Sepacore Flash System (2 x Büchi Pump Module C-605, Büchi Pump Manager C-615, Büchi UV Photometer C-635, Büchi Fraction Collector C-660) or a Reveleris Grace system using silica gel 60 (40-63 µm) as obtained from Merck and distilled or redistilled solvents. Preparative HPLC was done on a Reveleris Grace system. LC-MS measurements were carried out using an HPLC system from Agilent Technologies with the following components: Agilent 1200 Series G1367B HiP ALS autosampler, Agilent 1100 Series G1311A Quat Pump, Agilent 1100 Series G1379A Degasser, Agilent 1200 Series G1316B TCCSL, Agilent 1260 Infinity G1315D DAD as well as an Esquire HCT Ion Trap MS of Bruker as detectors. NMR spectra were recorded on a Bruker Avance IIIHD 600 MHz spectrometer equipped with a Prodigy BBO cryo probe, on a Bruker Avance UltraShield 400 spectrometer or on a Bruker AC200 spectrometer at 20 °C. Chemical shifts are reported in ppm (δ) relative to tetramethylsilane and calibrated using solvent residual peaks. Data is shown as follows: Chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, quin = quintet, sext = sextet, m = multiplet, br = broad signal) and integration. HR-MS analysis was carried out from 10 ppm solutions in MeCN/H2O (1:1) by using an HTC PAL system autosampler (CTC Analytics AG, Zwingen, Switzerland), an Agilent 1100/1200 HPLC with binary pumps, degasser and column thermostat (Agilent Technologies, Waldbronn, Germany) and Agilent 6230 AJS ESI-TOF mass spectrometer (Agilent Technologies, Palo Alto, United States). An Agilent 6230 LC TOFMS mass spectrometer equipped with an Agilent Dual AJS ESI-Source was used for the analysis. The mass spectrometer was connected to a liquid chromatography system of the 1100/1200 series from Agilent Technologies, Palo Alto, CA, USA. The system consisted of a 1200SL binary gradient pump, a degasser, column thermostat, and an HTC PAL autosampler (CTC Analytics AG, Zwingen, Switzerland). As stationary phase a silica-based C-18 column (4.6 x 50 mm) from Agilent and a Phenomenex C 18 Security Guard Cartridge was used. Data was analyzed using Agilent MassHunter Qualitative Analysis B.07.00. Identification was based on peaks obtained from extracted ion chromatograms (extraction width ± 20 ppm). 3-(4-(prop-2-yn-1-yloxy)phenyl)-1,2,4,5-tetrazine (1) (100 mg, 0.471 mmol, 1 eq) and 2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethan-1-amine (123 mg, 0.565 mmol, 1.2 eq) were dissolved in anhydrous DMF (3.5 mL) and acetate buffer (0.5 mL, 1 mol/L, pH = 6). The catalyst solution was prepared by mixing aqueous sodium ascorbate (25 µL, 300 mg/mL) and aqueous copper(II)sulfate pentahydrate solution (25 µL, 112 mg/mL). After 1.5 min the black color turned yellow and bathophenathroline disulfonic acid disodium salt trihydrate (BPDS) solution (100 µL, 50 mg/mL in water) was added. The color turned dark green and the catalyst solution was added immediately to the pink reaction mixture and was allowed to react at room temperature for 20 min. After full conversion as shown by LC-MS the reaction mixture was directly loaded onto a C18 column and reversed phase column chromatography (C18, 5-90% MeCN+0.1% formic acid in water+0.1% formic acid) afforded 2 (203 mg, quant). 1 
tert-Butyl (1-(4-((4-(1,2,4,5-tetrazin-3-yl)phenoxy)methyl)-1H-1,2,3-triazol-1-yl)-13-oxo-15-(4-(prop-2-yn-1-yloxy)phenyl)-3,6,9-trioxa-12-azapentadecan-14-yl)carbamate (4)
In a glass vial 2-((tert-butoxycarbonyl)amino)-3-(4-(prop-2-yn-1-yloxy)phenyl)propanoic acid (3) (22 mg, 0.07 mmol, 1 eq) and HBTU (31 mg, 0.08 mg, 1.2 eq) were dissolved in dry DMF (1 mL). DIPEA (36 mg, 0.28 mmol, 4 eq) was added and the mixture was stirred at room temperature for 5 min. 2 (42 mg, 0.09 mmol, 1.3 eq) was added and the mixture was stirred at room temperature for 3 h. The reaction mixture was directly loaded onto a C18 column and reversed phase column chromatography (C18, Phenomenex Luna 10u, 250 x 21.2 mm, 10 μm; 10-80% MeCN in water) gave 4 (18 mg, 35% 
2,2',2''-(10-(17-(4-((4-(1,2,4,5-Tetrazin-3-yl)phenoxy)methyl)-1H-1,2,3-triazol-1-yl)-2,5-dioxo-4-(4-(prop-2-yn-1-yloxy)benzyl)-9,12
,15-trioxa-3,6-diazaheptadecyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetic acid (5) 4 (20 mg, 0.027 mmol, 1 eq) was dissolved in anhydrous DCM (1.5 mL) and trifluoroacetic acid (TFA) (500 µL) was added. The dark orangecolored solution was stirred at room temperature for 35 min until LC-MS showed full conversion. The reaction mixture was dried by co-evaporation with MeCN (3 x 500 µL) and the residue was dissolved in anhydrous DMF (0.5 mL). DIPEA (52 mg, 0.405 mmol, 15 eq) and DOTA-NHS ester (50 mg, 0.062 mmol, 2.3 eq) were added and the pink-colored reaction mixture was stirred at room temperature for 80 min. After full conversion as shown by LC-MS the reaction mixture was directly loaded onto a C18 column and reversed phase column chromatography (C18, 5-90% MeCN+0.1% formic acid in water+0.1% formic acid) afforded 5 (27 mg, 99% 
Yttrium complex (Y-6)
5 (5 mg, 5 µmol, 1 eq) was dissolved in acetate buffer (0.7 mL, 1 mol/L, pH = 6) and yttrium acetate hydrate (84 mg, 0.219 mmol, 45 eq) was added over a period of 120 min. The reaction was stirred at 42 °C for 120 min and for additional 60 min the temperature was increased to 55 °C. After LC-MS showed full conversion the reaction mixture was purified using a C18 reversed phase cartridge (Sep-Pak; Waters Corp., Milford, MA, USA) to give Y-6 (5.4 mg, quant 
2-((tert-Butoxycarbonyl)amino)-3-(4-((1-(2-fluoroethyl)-1H-1,2,3-triazol-4-yl)methoxy)phenyl)propanoic acid (7)
2-((tert-butoxycarbonyl)amino)-3-(4-(prop-2-yn-1-yloxy)phenyl)propanoic acid (1) (200 mg, 0.626 mmL, 1 eq) and 1-azido-2-fluoroethane (67 mg in 500 µL anhydrous DMF, 0.752 mmol, 1.2 eq) were mixed in anhydrous DMF (2 mL) and acetate buffer (1 mL, 1 mol/L, pH = 6). To prepare the catalyst solution, aqueous sodium ascorbate (15 µL, 300 mg/mL) and aqueous copper(II)sulfate pentahydrate (15 µL, 112 mg/mL) were mixed in an Eppendorf® tube. After 90 seconds the black colored solution turned yellow and bathophenathroline disulfonic acid disodium salt trihydrate (BPDS) solution (60 µL, 50 mg/mL in water) was added. The color turned dark green and the catalyst solution was added to the colorless reactant mixture. After reacting at room temperature for 30 min LC-MS showed full conversion. The reaction mixture was diluted with water (containing 0.1% TFA) and purified by column chromatography (C18, 10-90% MeCN+0.1% formic acid in water+0.1% formic acid) to give 7 (214 mg, 84%). 1 (1-(4-((4-(1,2,4,5-tetrazin-3-yl)phenoxy)methyl)-1H-1,2,3-triazol-1-yl)-15-(4-((1-(2-fluoroethyl)-1H-1,2,3-triazol-4-yl) 8 (15 mg, 0.019 mmol, 1 eq) was dissolved in anhydrous DCM (1 mL) and TFA (250 µL) was added. The orangecolored solution was stirred at room temperature for 30 min until LC-MS showed full conversion. The reaction mixture was dried azeotropically by co-evaporation with acetonitrile (3 times 500 µL MeCN) and the residue was dissolved in anhydrous DMF (0.5 mL). DIPEA (36 mg, 0.278 mmol, 15 eq) and DOTA-NHS (30 mg, 0.037 mmol, 2 eq) were added and the pink-colored reaction mixture was stirred at room temperature for 50 min. After full conversion as shown by LC-MS the reaction mixture was directly loaded onto a C198 column and reversed phase column chromatography (C18, 5-90% MeCN+0.1% formic acid in water+0.1% formic acid) gave 9 (14.5 mg, 71%). 
tert-Butyl

Metal complexes 10 (Reference compounds)
Holmium complex (F-Ho-10) 9 (2 mg, 2 µmol, 1 eq) was dissolved in acetate buffer (0.5 mL, 1 mol/L, pH = 6) and holmium acetate hydrate (9.3 mg, 0.027 mmol, 15 eq) was added. After 60 min at 45 °C LC-MS showed full conversion and the reaction mixture was purified using a C18 reversed phase cartridge (Sep-Pak; Waters Corp., Milford, MA, USA) to give F-Ho-10 (2.3 mg, quant 
Lutetium complex (F-Lu-10)
9 (2 mg, 2 µmol, 1 eq) was dissolved in acetate buffer (0.5 mL, 1 mol/L, pH = 6) and lutetium acetate hydrate (9.5 mg, 0.027 mmol, 15 eq) was added. After 30 min at 40 °C LC-MS showed full conversion and the reaction mixture was purified using a C18 reversed phase cartridge (Sep-Pak; Waters Corp., Milford, MA, USA) to give F-Lu-10 (2.3 mg, quant). ESI-MS [M+H + ] calcd. 1278.4, found 1279.4.
Yttrium complex (F-Y-10)
9 (2 mg, 2 µmol, 1 eq) was dissolved in acetate buffer (0.5 mL, 1 mol/L, pH = 6) and yttrium acetate hydrate (10.3 mg, 0.027 mmol, 15 eq) was added. The reaction was stirred for 60 min at 40 °C and additional 30 min at 45°C. The reaction mixture was purified after LC-MS showed full conversion using a C18 reversed phase cartridge (Sep-Pak; Waters Corp., Milford, MA, USA) to give F-Y-10 (2.1 mg, quant 
ACUPA-TCO (11)
Di-tert-butyl ((6-amino-1-(tert-butoxy)-1-oxohexan-2-yl)carbamoyl)-glutamate 5 (17 mg, 0.034 mmol, 1 eq) was dissolved in DCM (0.5 mL) and TFA (200 µL) was added. The reaction mixture was allowed to stir at room temperature overnight and then evaporated to dryness. Remaining TFA was removed by co-evaporation with acetonitrile (3x). The residue was dissolved in DMF (1 mL) and (E)-cyclooct-4-en-1-yl (2,5-dioxopyrrolidin-1-yl)carbonate 6 (11 mg, 0.041 mmol, 1.2 eq) and DIPEA (44 mg, 0.340 mmol, 8 eq) were added. The reaction mixture was stirred at room temperature for 60 min. After full conversion was shown by LC-MS the reaction mixture was purified using column chromatography (C18, 5-90% MeCN+0.1% formic acid in water+0.1% formic acid) to give 11 (13 mg, 81% 
Pretargeted (bioorthogonal reaction of PSMA-bound ACUPA-TCO + [ 18 F]F-Y-10)
LNCaP cells were incubated for 90 min in medium including TCO-modified PSMA-ligand 11 (500 nM and 1000 nM). After washing with medium (0.5 mL/well) cells were incubated for 90 min with [ 18 F]F-Y-10 (purified) in medium followed by washing with medium (0.5 mL/well) and PBS (0.2 mL).
Cells were detached using 0.25% trypsin (0.2 mL/well, 10 min) and transferred with medium (0.8 mL) into a gamma-counting vial. Measurements were done using a HIDEX automatic gamma counter.
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